Back

What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term?

31 August 2020 (18:35 - 18:44)
Organised by:
Congress Presentation Part of: Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy Drug therapy Open Access ESC Congress 2020

About the speaker

Photo
Doctor Leopoldo Perez De Isla

San Carlos Clinical University Hospital, Madrid (Spain)

6 More presentations in this session

Presentation thumbnail
ESC Guidelines 2019: what has changed?
Professor A. Zambon (Padua, IT)
Slides Video
Presentation thumbnail
Broader usage of combinations in daily clinical practice: what benefits for patients?
Professor A. Zambon (Padua, IT)
Slides Video
Presentation thumbnail
How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations.
Professor L. Perez De Isla (Madrid, ES)
Slides Video
Presentation thumbnail
Statin/ezetimibe combinations: data and evidence, for which patients.
Professor A. Zambon (Padua, IT)
Slides Video
Presentation thumbnail
Feedback on patients treated with high intensity statin/ezetimibe combinations. Do we need to go further?
Professor A. Zambon (Padua, IT)
Slides Video

Access the full session

Session thumbnail
Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy
Video

The Event

Event poster

ESC Congress 2020

31 August 2020 18:35 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources